Reported Earnings • 5h
Full year 2026 earnings released: EPS: ₹18.65 (vs ₹15.71 in FY 2025) Full year 2026 results: EPS: ₹18.65 (up from ₹15.71 in FY 2025). Revenue: ₹3.56b (up 34% from FY 2025). Net income: ₹438.6m (up 33% from FY 2025). Profit margin: 12% (in line with FY 2025). お知らせ • Jul 06
Accent Microcell Limited, Annual General Meeting, Jul 31, 2026 Accent Microcell Limited, Annual General Meeting, Jul 31, 2026, at 11:00 Indian Standard Time. Reported Earnings • May 13
Full year 2026 earnings released: EPS: ₹18.65 (vs ₹15.71 in FY 2025) Full year 2026 results: EPS: ₹18.65 (up from ₹15.71 in FY 2025). Revenue: ₹3.56b (up 34% from FY 2025). Net income: ₹438.6m (up 33% from FY 2025). Profit margin: 12% (in line with FY 2025). お知らせ • May 08
Accent Microcell Limited to Report Second Half, 2026 Results on May 12, 2026 Accent Microcell Limited announced that they will report second half, 2026 results on May 12, 2026 New Risk • May 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (58% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Market cap is less than US$100m (₹8.95b market cap, or US$94.4m). Valuation Update With 7 Day Price Move • Apr 06
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹409, the stock trades at a trailing P/E ratio of 24.8x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 121% over the past year. New Risk • Dec 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (58% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (₹7.22b market cap, or US$80.3m). Board Change • Nov 10
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Chintan Bhatt was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. お知らせ • Aug 23
Accent Microcell Limited announces Annual dividend, payable on October 25, 2025 Accent Microcell Limited announced Annual dividend of INR 1.0000 per share payable on October 25, 2025, ex-date on September 16, 2025 and record date on September 16, 2025. お知らせ • Aug 22
Accent Microcell Limited, Annual General Meeting, Sep 25, 2025 Accent Microcell Limited, Annual General Meeting, Sep 25, 2025, at 11:00 Indian Standard Time. New Risk • Jul 31
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 7.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (7.8% average weekly change). High level of non-cash earnings (36% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Market cap is less than US$100m (₹5.93b market cap, or US$67.7m). Valuation Update With 7 Day Price Move • Jul 31
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹316, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 17% over the past year. Valuation Update With 7 Day Price Move • Jun 30
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹266, the stock trades at a trailing P/E ratio of 16.9x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Negligible returns to shareholders over past year. New Risk • Jun 08
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (38% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Paying a dividend despite having no free cash flows. Market cap is less than US$100m (₹4.84b market cap, or US$56.4m). Valuation Update With 7 Day Price Move • May 14
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹239, the stock trades at a trailing P/E ratio of 15.5x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total loss to shareholders of 23% over the past year. New Risk • Dec 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (38% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (₹6.20b market cap, or US$72.9m). Reported Earnings • Oct 20
First half 2025 earnings released: EPS: ₹7.83 (vs ₹8.54 in 1H 2024) First half 2025 results: EPS: ₹7.83. Revenue: ₹1.26b (down 7.5% from 1H 2024). Net income: ₹164.7m (up 2.5% from 1H 2024). Profit margin: 13% (up from 12% in 1H 2024). The increase in margin was driven by lower expenses. お知らせ • Sep 09
Accent Microcell Limited Declares Final Dividend for the Financial Year Ended March 31, 2024 Accent Microcell Limited declared a final Dividend of INR 01/- per fully paid-up equity share of INR 10/- each for the Financial Year Ended March 31, 2024. お知らせ • Aug 05
Accent Microcell Limited, Annual General Meeting, Sep 09, 2024 Accent Microcell Limited, Annual General Meeting, Sep 09, 2024, at 11:30 Indian Standard Time. New Risk • May 19
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 38% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (38% accrual ratio). Minor Risk Market cap is less than US$100m (₹6.90b market cap, or US$82.9m). Reported Earnings • May 19
Full year 2024 earnings released: EPS: ₹18.67 (vs ₹10.06 in FY 2023) Full year 2024 results: EPS: ₹18.67 (up from ₹10.06 in FY 2023). Revenue: ₹2.49b (up 22% from FY 2023). Net income: ₹301.7m (up 132% from FY 2023). Profit margin: 12% (up from 6.4% in FY 2023). The increase in margin was driven by higher revenue. お知らせ • May 18
Accent Microcell Limited Recommends Dividend for the Financial Year Ended 31 March, 2024 Accent Microcell Limited announced that at its Board of Directors meeting held on May 17, 2024, recommended a final dividend at the rate of 10% on the Equity share capital of the company i.e. INR 1/- per equity share of INR 10/- each for the financial year ended 31 March, 2024, subject to the approval of shareholders at the Annual General Meeting of the Company. Valuation Update With 7 Day Price Move • May 14
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹305, the stock trades at a trailing P/E ratio of 49.3x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Valuation Update With 7 Day Price Move • Apr 03
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹269, the stock trades at a trailing P/E ratio of 43.4x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Recent Insider Transactions • Mar 19
CFO, MD & Director recently bought ₹21m worth of stock On the 14th of March, Ghanshyam Patel bought around 91k shares on-market at roughly ₹231 per share. This transaction amounted to 3.3% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth ₹36m. Ghanshyam has been a buyer over the last 12 months, purchasing a net total of ₹57m worth in shares. Recent Insider Transactions • Jan 20
CFO, MD & Director recently bought ₹36m worth of stock On the 16th of January, Ghanshyam Patel bought around 120k shares on-market at roughly ₹301 per share. This transaction increased Ghanshyam's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Ghanshyam's only on-market trade for the last 12 months. Board Change • Dec 15
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Chintan Bhatt was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.